Why AngioDynamics Stock Is Tumbling Today

Actions of Angiodynamics (ANGO -17.44%) they tumbled 17.1% lower as of 10:43 a.m. ET Thursday. The steep selloff came after the medical technology company announced its fiscal first quarter 2025 update.

AngioDynamics reported fiscal first quarter net sales of $67.5 million, up 1.1% year-over-year. This result was slightly lower than analysts’ average revenue estimate of $67.93 million.

The company posted a net loss of $12.8 million, or $0.31 per share, on a generally accepted accounting principles (GAAP) basis. Its adjusted net loss was $4.4 million, or $0.11 per share — better than the consensus estimate of an adjusted loss of $0.15 per share.

Some good news for AngioDynamics

The company has had some good news recently. Last month, it submitted to the US Food and Drug Administration (FDA) the results of a pivotal study of the NanoKnife system for ablation of prostate tissue in intermediate-risk patients. AngioDynamics hopes to win 510(k) clearance based on this submission.

The company also received European CE Mark approval for its Auryon Atherectomy System in the treatment of peripheral artery disease. This system was approved by the FDA in 2020.

Also, despite mixed results for AngioDynamics in its fiscal first quarter, the medtech company maintained its previous guidance for the full year. AngioDynamics continues to expect net sales between $282 million and $288 million, reflecting growth of 4.2% to 6.4% year over year. It also projects bottom line improvement, with adjusted net loss per share between $0.38 and $0.42, compared to a pro forma adjusted loss per share of $0.45 in fiscal 2024.

Are you buying AngioDynamics stock on the dip?

Some investors may be tempted to get shares of AngioDynamics after its latest pullback. However, the company’s growth is not something to get excited about. I think many other stocks offer more attractive risk-reward propositions.